Top Markets
Coin of the day
Q BioMed Inc. Q BioMed Inc.

Q BioMed Inc.

QBIO
株式のランク #41615
Q BioMed Inc. functions as a biomedical accelerator and developer, actively... Q BioMed Inc. functions as a biomedical accelerator and developer, actively licensing, acquiring, and supplying resources to firms within the life sciences and healthcare sectors. Its commercial portfolio includes Metastron (Strontium Chloride SR89), a radiopharmaceutical designed to alleviate pain associated with metastatic bone cancer. Additionally, Q BioMed is advancing a pipeline of therapeutic candidates, including Man-01, a pre-clinical compound aimed at primary open-angle glaucoma; QBM-001, intended for rare pediatric non-verbal autism spectrum disorder; and Uttroside-B, which targets liver cancer. The company also collaborates with Mannin Research Inc. on the development of treatments for conditions such as acute respiratory distress syndrome, glaucoma, and various kidney diseases. Incorporated in New York, New York, in 2013, the entity was initially named ISMO Tech Solutions, Inc. before adopting its current name, Q BioMed Inc., in July 2015.
株価
$0.0001
最終同期: 2026-04-02
時価総額
$14.51K
変化(1日)
0.00%
変化(1年)
9,900.00%
US
取引 Q BioMed Inc. (QBIO)

カテゴリー

Q BioMed Inc.(QBIO)の収益
Aug 2026 時点の収益 TTM: 0
Q BioMed Inc. の最新の財務報告によると、現在の収益 (TTM) は 0 です。2026 年には 0 の収益があり、これは 2026 年の 0 と比較して 同等 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
Q BioMed Inc. の収益履歴(2026 ~ 2026)
各年末の収益
収益 変化
提供された日付のデータは十分ではありません。
同業他社の収益
企業 収益 収益の差
$12.62B -
US
$6.02B -
NL
- -
CH
$10.11B -
BE
- -
KR